Skip to main content

Table 2 Antimicrobial susceptibility and MICs of 71 Nocardia isolates in clinical infections in Henan China from 2017 to 2023

From: Clinical characteristics and drug resistance of Nocardia in Henan, China, 2017–2023

Drugs Breakpoint

 

Species/complex, no. of strains (%)a

       

N.farcinica,

N.abscessus complex,16 (22.5)b

N. cyriacigeorgica,

N.amamiensis,

N.otitidiscaviarum, 5(7.0)

N. wallacei,

N. africana,

N.flavorosea,

N.puris,

N.pseudobrasiliensis, 1 (1.4)

N.rhamnosiphila, (1.4)

19(26.8)

13,(18.3)

8(11.3)

3(4.2)

2(2.8)

2 (2.8)

1 (1.4)

TMP-SMX (S ≤ 2/38, R ≥ 4/76)

MIC50

 ≤ 0.25/4.75

 ≤ 0.25/4.75

 ≤ 0.25/4.75

 ≤ 0.25/4.75

0.5/9.5

 ≤ 0.25/4.75

     
 

MIC90

1/19

1/19

1/19

0.5/9.5

2/38

1/19

     
 

S/R (%)

100/0

100/0

100/0

100/0

100/0

100/0

100/0

100/0

100/0

100/0

100/0

Linezolid (S ≤ 8, ~)

MIC50

 ≤ 1

 ≤ 1

 ≤ 1

 ≤ 1

 ≤ 1

 ≤ 1

     
 

MIC90

2

 ≤ 1

 ≤ 1

 ≤ 1

2

 ≤ 1

     
 

S/NS (%)

100/0

100/0

100/0

100/0

100/0

100/0

100/0

100/0

100/0

100/0

100/0

Ciprofloxacin (S ≤ 1, R ≥ 4)

MIC50

1

 > 4

 > 4

 > 4

2

1

     
 

MIC90

4

 > 4

 > 4

 > 4

4

2

     
 

S/I/R (%)

78.9/10.5/10.5

18.8/18.8/62.5

0/0/100

0/0/100

20/40/40

66.7/33.3/0

0/50/50

100/0/0

0/0/100

0/0/100

100/0/0

Imipenem (S ≤ 4, R ≥ 16)

MIC50

8

4

 ≤ 2

4

64

8

     
 

MIC90

32

64

16

8

 > 64

 > 64

     
 

S/I/R (%)

26.3/26.3/47.4

50/0/50

61.5/23.1/15.4

75/25/0

0/0/100

33.3/33.3/33.3

0/0/100

100/0/0

100/0/0

0/100/0

100/0/0

Moxifloxacin (S ≤ 1, R ≥ 4)

MIC50

0.5

8

2

4

1

 ≤ 0.25

     
 

MIC90

2

16

4

8

2

1

     
 

S/I/R (%)

84.2/10.5/5.3

25/18.8/56.2

7.7/61.5/30.8

0/12.5/87.5

60/40/0

100/0/0

100/0/0

100/0/0

100/0/0

0/100/0

100/0/0

Cefepime

MIC50

 > 32

4

16

4

 > 32

4

     
 

MIC90

 > 32

16

 > 32

 > 32

 > 32

32

     
 

Range

16 to > 32

 ≤ 1 to 32

2 to > 32

2 to > 128

 ~  > 32

4 to 32

     

AUG (S ≤ 8/4, R ≥ 32/16)

MIC50

8/4

16/8

16/8

16/8

 > 64/32

8/4

     
 

MIC90

16/8

 > 64/32

32/16

16/8

 > 64/32

16/8

     
 

S/I/R (%)

52.6/42.1/5.3

43.8/6.2/50

0/53.8/46.2

37.5/62.5/0

0/0/100

66.7/33.3/0

0/0/100

50/0/50

0/0/100

0/100/0

0/0/100

Amikacin (S ≤ 8, R ≥ 16)

MIC50

 ≤ 1

 ≤ 1

 ≤ 1

 ≤ 1

 ≤ 1

2

     
 

MIC90

 ≤ 1

 ≤ 1

 ≤ 1

2

 ≤ 1

16

     
 

S/I/R (%)

100/0/0

100/0/0

100/0/0

100/0/0

100/0/0

66.7/0/33.3

100/0/0

100/0/0

100/0/0

100/0/0

100/0/0

Ceftriaxone (S ≤ 8, R ≥ 64)

MIC50

64

4

 ≤ 4

 ≤ 4

 > 64

8

     
 

MIC90

 > 64

8

64

64

 > 64

32

     
 

S/I/R (%)

5.3/15.8/78.9

93.8/6.2/0

76.9/7.7/15.4

87.5/0/12.5

0/20/80

66.7/33.3/0

0/0/100

50/50/0

100/0/0

0/0/100

100/0/0

Doxycycline (S ≤ 1, R ≥ 8)

MIC50

2

0.12

2

 ≤ 0.12

1

2

     
 

MIC90

4

0.5

2

2

2

2

     
 

S/I/R (%)

26.3/73.7/0

93.8/6.2/0

46.2/53.8/0

87.5/12.5/0

60/40/0

0/100/0

0/100/0

50/50/0

100/0/0

0/0/100

100/0/0

Minocycline (S ≤ 1, R ≥ 8)

MIC50

2

 ≤ 1

 ≤ 1

 ≤ 1

 ≤ 1

2

     
 

MIC90

2

 ≤ 1

2

 ≤ 1

2

2

     
 

S/I/R (%)

36.8/63.2/0

93.8/6.2/0

61.5/38.5/0

100/0/0

80/20/0

33.3/66.7/0

50/50/0

50/50/0

100/0/0

0/0/100

100/0/0

Tobramycin (S ≤ 4, R ≥ 16)

MIC50

16

 ≤ 1

 ≤ 1

 ≤ 1

2

 > 16

     
 

MIC90

 > 16

 ≤ 1

 ≤ 1

8

4

 > 16

     
 

S/I/R (%)

5.3/15.8/78.9

100/0/0

100/0/0

87.5/12.5/0

100/0/0

33.3/0/66.7

100/0/0

100/0/0

100/0/0

100/0/0

100/0/0

Clarithromycin (S ≤ 2, R ≥ 8)

MIC50

 > 16

1

2

0.06

16

0.5

     
 

MIC90

 > 16

 > 16

 > 16

4

 > 16

16

     
 

S/I/R (%)

5.3/5.3/89.4

56.2/6.2/37.5

69.2/7.7/23.1

87.5/12.5/0

20/20/60

66.7/0/33.3

0/0/100

50/50/0

0/0/100

100/0/0

100/0/0

Cefoxitin

MIC50

64

8

64

16

 > 128

64

     
 

MIC90

 > 128

16

 > 128

 > 128

 > 128

128

     
 

Range

32 to > 128

 ≤ 4 to 128

16 to > 128

 ≤ 4 to > 128

128 to > 128

64 to 128

     

Tigecycline

MIC50

0.5

0.25

0.25

0.06

0.25

0.25

     
 

MIC90

2

0.5

1

0.25

0.5

0.5

     
 

Range

0.03 to 4

 ≤ 0.015 to 1

0.12 to 1

0.03 to 0.25

0.06 to 0.5

0.25 to 0.5

     
  1. Nocardia species/complex responsible for clinical infections in Henan China from 2017 to 2023. TMP-SMX, trimethoprim-sulfamethoxazole. AUG, Amoxicillin-clavulanic acid
  2. S, susceptible; I, intermediate; R, resistant; NS, nonsusceptible; MIC50 and MIC90,MICs at which 50% and 90% of the strains were inhibited, respectively
  3. The table shows the antimicrobial susceptibilities profifiles and MIC values (in mg/mL) (as determined by the broth microdilution method) to 15 antibiotics of the major
  4. aPercentage with respect to the total number of identifified Nocardia strains (n = 71)
  5. bN. abscessus complex (16) includes N. abscessus (8), N. asiatica (3), and N. beijingensis (5)